{rfName}

License and Use

Icono OpenAccess

Altmetrics

Analysis of institutional authors

Aiello TfCorresponding AuthorChumbita MAuthorMonzó PAuthorPuerta-Alcalde PAuthorMagnano LAuthorFernández-Avilés FAuthorMensa JAuthorEsteve JAuthorSoriano AAuthorGarcia-Vidal CCorresponding Author

Share

March 14, 2024
Publications
>
Article

Real-Life Comparison of Antivirals for SARS-CoV-2 Omicron Infection in Patients With Hematologic Malignancies.

Publicated to: Influenza and Other Respiratory Viruses. 18 (3): e13264- - 2024-03-11 18(3), DOI: 10.1111/irv.13264

Authors:

Aiello, Tommaso Francesco; Peyrony, Olivier; Chumbita, Mariana; Monzo, Patricia; Lopera, Carlos; Puerta-Alcalde, Pedro; Magnano, Laura; Fernandez-Aviles, Francesc; Cuesta, Genoveva; Tuset, Montse; Mensa, Josep; Esteve, Jordi; Marcos, Maria Angeles; Soriano, Alex; Garcia-Vidal, Carolina
[+]

Affiliations

Department of Haematology, Hospital Clinic of Barcelona-IDIBAPS, University of Barcelona, Barcelona, Spain. - Author
Department of Pharmacy, Hospital Clinic of Barcelona-IDIBAPS, University of Barcelona, Barcelona, Spain. - Author
Emergency Department, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris, Paris, France. - Author
Hop St Louis, Assistance Publ Hop Paris, Emergency Dept, Paris, France - Author
Infectious Diseases Department, Hospital Clinic of Barcelona-IDIBAPS, Universitat de Barcelona, Barcelona, Spain. - Author
Infectious Diseases Department, Hospital Clinic of Barcelona-IDIBAPS, Universitat de Barcelona, Barcelona, Spain.; Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, Spain. - Author
Microbiology Department, Hospital Clinic, University of Barcelona, ISGLOBAL, Barcelona, Spain. - Author
Univ Barcelona, Fac Med & Ciencies Salut, Barcelona, Spain - Author
Univ Barcelona, Hosp Clin Barcelona, Dept Haematol, IDIBAPS, Barcelona, Spain - Author
Univ Barcelona, Hosp Clin Barcelona, Dept Pharm, IDIBAPS, Barcelona, Spain - Author
Univ Barcelona, Hosp Clin Barcelona, Infect Dis Dept, IDIBAPS, Barcelona, Spain - Author
Univ Barcelona, Hosp Clin, Microbiol Dept, ISGLOBAL, Barcelona, Spain - Author
See more

Abstract

BackgroundWe aimed to describe a cohort of hematologic patients with COVID-19 treated with antivirals early.MethodsNon-interventional chart review study. Comparison of baseline characteristics and outcomes in high-risk hematologic patients treated with remdesivir between December 2021 and April 2022 versus those treated with nirmatrelvir/ritonavir between May and August 2022.ResultsEighty-three patients were analyzed. Forty-two received remdesivir, and 41 nirmatrelvir/ritonavir. Patients with remdesivir were younger, vaccinated with lower number of doses, and received prior corticosteroids less frequently and sotrovimab, hyperimmune plasma and corticosteroids more often. Viral shedding median (IQR) duration was 18 (13-23) and 11 (8-21) days in the remdesivir and nirmatrelvir/ritonavir groups, respectively (p = 0.004). Median (IQR) Ct values before treatment were similar in both groups. Within 5 days of treatment, median (IQR) Ct values were 26 (23-29) and 33 (30-37) in the remdesivir and nirmatrelvir/ritonavir groups, respectively (p < 0.0001). All patients were hospitalized for remdesivir administration and only four (9.8%) in the nirmatrelvir/ritonavir group. The overall outcomes in this cohort of COVID-19 patients with Omicron variant was good, as no patient needed oxygen or ICU admission. One patient in remdesivir group died from septic shock. No severe adverse event was recorded in both treatment groups.ConclusionsPatients with hematologic malignancies and non-severe COVID-19 who received nirmatrelvir/ritonavir experienced faster decrease in viral load and shorter viral shedding. Furthermore, besides the advantage of oral administration, nirmatrelvir/ritonavir administration reduced the need of hospital admission.
[+]

Keywords

Adrenal cortex hormonesAdultAgedAntiviral agentsAntivirus agentArticleCancer chemotherapyCause of deathCohort analysisCoronavirus disease 2019CorticosteroidCovid-19Covid-19 drug treatmentCovid-19 pharmacotherapyDisease durationDrug effectEscherichia coli infectionFemaleHematologic diseaseHematologic malignancyHematologic neoplasmsHodgkin diseaseHumanHumansInfection preventionLactamLactamsLeucineMajor clinical studyMaleNirmatrelvirNirmatrelvir plus ritonavirNirmatrelvir/ritonavirNitrileNitrilesNonhumanObservational studyOmicronOutcomeOutcome assessmentPhenotypesProlineRemdesivirRitonavirRituximabSars-cov-2Sars-cov-2 omicronSars-cov-2 vaccineSars-cov-2 variantsSeptic shockSevere acute respiratory syndrome coronavirus 2Sex ratioSotrovimabVaccinationVirus shedding

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Influenza and Other Respiratory Viruses due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2024 there are still no calculated indicators, but in 2023, it was in position 25/137, thus managing to position itself as a Q1 (Primer Cuartil), in the category Infectious Diseases.

Independientemente del impacto esperado determinado por el canal de difusión, es importante destacar el impacto real observado de la propia aportación.

Según las diferentes agencias de indexación, el número de citas acumuladas por esta publicación hasta la fecha 2026-04-04:

  • WoS: 5
  • Scopus: 3
  • Europe PMC: 6
[+]

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2026-04-04:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 8.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 8 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 12.
  • The number of mentions on the social network X (formerly Twitter): 3 (Altmetric).
  • The number of mentions in news outlets: 1 (Altmetric).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.
[+]

Leadership analysis of institutional authors

This work has been carried out with international collaboration, specifically with researchers from: France.

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: First Author (Aiello, Tommaso Francesco) and Last Author (Garcia Vidal, Carolina).

the authors responsible for correspondence tasks have been Aiello, Tommaso Francesco and Garcia Vidal, Carolina.

[+]